Florida Cancer Affiliates Names New Executive Director
“We are excited to bring John’s energy, expertise and new ideas to our practice,” said Lawrence Hochman, DO, FACRO, practice president, Florida Cancer Affiliates. “In his new role, John will focus on providing leadership and operational direction for our clinics, as well as ensuring financial performance. His extensive experience running several large medical facilities will be a great asset to us as we continue with our mission of providing patients compassionate, quality care and convenient access to leading-edge, evidence-based treatments.”
Prior to joining Florida Cancer Affiliates, Brown had his own consulting firm where he provided operational management services to various types of medical facilities. Before that, he was Chief Executive Officer of Medical Specialists of the Palm Beaches, a 78-physician multi-specialty practice with 30 locations based in Lake Worth, Fla. Preceding his work in Florida, he was Chief Executive Officer of Cardiology Consultants, a 33-provider cardiology group in Virginia with multiple treatment centers. He also spent 13 years as President/Chief Executive Officer of Blair Medical Associates, a large multi-specialty group in Altoona, Pa. At all three practices, he launched many new initiatives that improved practice efficiency and quality care, increased service offerings and enhanced revenue cycle management.
“John brings a tremendous amount of experience, expertise and energy to FCA,” said Maureen McGrath, executive director of Virginia Oncology Associates, another practice in The US Oncology Network. “My team and I eagerly welcome him to The US Oncology Network.”
Brown holds a Master’s Degree in Business Administration from Clarion University of Pennsylvania and a Bachelor of Science Degree in Health Planning and Administration from Pennsylvania State University, where he was also an adjunct faculty member. He is Board Certified by the American College of Medical Practice Executives, having earned the Certified Medical Practice Executive (CMPE) credential that validates and verifies expertise and experience in medical practice management.
“The great reputation of Florida Cancer Affiliates is well known in the area,” said Brown. “I look forward to bringing the leadership and process improvement tools to provide the ultimate experience for our patients and referring physicians.”
About Florida Cancer Affiliates
Florida Cancer Affiliates (FCA) is a community-based radiation oncology, medical oncology, and hematology practice with convenient locations throughout Florida, from Naples and Ft. Myers to Trinity, Hudson, Brooksville, The Villages, Ocala and Panama City. The integrated clinical team of FCA employs the latest technologies and drug therapies to ensure patients receive advanced care close to home. The comprehensive treatment centers include outpatient treatment and diagnostic facilities providing chemotherapy, hematology services, radiation therapy including stereotactic and PET/CT imaging, clinical research, pharmacy and laboratory, as well as financial counseling and patient support services.
The practice is committed to providing patients with advanced care. They offer therapies proven to be effective, along with advanced diagnostic and treatment technologies. They also provide access to new investigational drugs through clinical trials. By participating in clinical trials that test new drugs or various combinations of treatments, patients have the opportunity to receive new therapies not yet available outside these clinical trials. To learn more about Florida Cancer Affiliates, go to www.floridacancer.com.
Florida Cancer Affiliates is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. As an affiliate of The US Oncology Network, FCA is united with 1,000 physicians nationwide. Florida Cancer Affiliates participates in clinical trials through US Oncology Research, which has played a role in more than 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.
Комментарии